The Form 4 filing, which reports an insider's stock trades, was filed on November 12, 2026. The sales took place on November 11, 2026. The filing lists Richard Pulik as chief financial officer of Roivant Sciences Ltd. (ROIV).
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-11 |
| Date of Latest Transaction | 2026-11-11 |
| Buy/Sell | sell |
| Transaction Count | 3 |
| Shares Transacted | 175,000 |
| Price | $41.85 |
| Total Transaction Value | $7,323,271.90 |
| Insider | |
| Ticker Symbol | ROIV |
| Company | Roivant Sciences Ltd. |
| Insider Name | Pulik Richard |
| Insider Title | CFO |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 222,046 |
| Position Size Change | 44.08% |
| Filing | |
| Filing Date | 2026-11-12 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were share sales under transaction code S. The report covers three sale transactions by one insider in one filing.
What was the average price of the transaction?
The average sale price was $41.85 per share, rounded from $41.847268. This average covers all three sales. Separate prices for each sale are not available in the transaction details.
How did this transaction affect the insider's holdings?
Richard Pulik sold 175,000 shares and reported owning 222,046 shares afterward. The shares sold made up 44.08% of his reported share balance before the sales.
What's the total transaction value?
The three sales had a total value of $7,323,271.90. Separate dollar values for each sale are not available in the transaction details.
Are there any special circumstances around this transaction?
The available transaction information did not identify a special arrangement for these sales. No filing footnote text was provided, so any further terms or explanations in those notes remain unknown. The details do not state why the shares were sold.
For research purposes only; not investment advice.